Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 4/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.41 |
| ▸ | HMOX1 | P09601 | 3/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14690054 | 0.83 | ERN1 (0.43) | FFAR4FFAR1ERN1HMOX1PTGS2 | |
| SCHEMBL3851503 | 0.82 | NQO1 (0.45) | FFAR4FFAR1ERN1ALDH1A1MAPT | |
| SCHEMBL289510 | 0.82 | CTSL (0.43) | FFAR4FFAR1ERN1HMOX1SSTR5 | |
| SCHEMBL2599795 | 0.81 | FFAR4 (0.47) | FFAR4ERN1ALOX5APFEN1 | |
| SCHEMBL2599698 | 0.79 | ERN1 (0.42) | FFAR4FFAR1ERN1CHRNA7PTGS2 | |
| SCHEMBL7247955 | 0.77 | ERN1 (0.57) | FFAR4FFAR1ERN1CHRNA7ALDH1A1 | |
| SCHEMBL3170130 | 0.76 | NQO1 (0.45) | FFAR4FFAR1ERN1ALDH1A1MAPT | |
| SCHEMBL9751747 | 0.75 | NQO1 (0.54) | FFAR4FFAR1CHRNA7ALDH1A1CYP11B1 | |
| SCHEMBL1547853 | 0.75 | NQO1 (0.56) | FFAR4FFAR1CHRNA7ALDH1A1MAPT | |
| SCHEMBL19497944 | 0.74 | ERN1 (0.54) | FFAR4FFAR1ERN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040978-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | MERCK SHARP & DOHME CORP | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040978-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | SSTR5, SSTR2, SSTR1 | FFAR4 122/4885FFAR1 113/4885ERN1 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.